New combo therapy aims to boost immune attack on liver tumors

NCT ID NCT06133062

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding proton radiotherapy to standard immunotherapy (atezolizumab and bevacizumab) can better control advanced liver cancer that cannot be removed by surgery. About 45 participants will receive the combination treatment. The study will measure how long the cancer stays under control and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs) plus proton radiotherapy
What this could lead to: If successful, this combination could improve tumor control and survival for people with advanced liver cancer that cannot be surgically removed.
What could go wrong: This is a small, early-phase trial (45 participants) without a comparison group, so results may not be definitive. Side effects from the drugs and radiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA NON-RESECTABLE

Contacts and locations

Locations

Chang Gung Memorial Hospital at Linkou
RECRUITING

Taoyuan City, Taiwan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.